10x Genomics, Inc.

NASDAQ:TXG

Medical - Healthcare Information Services

Healthcare
$57.07 +7.75%

+$2.49 today

Market cap
$6.93B
Beta
2.11
P/E (TTM)
-196.0
EPS (TTM)
-$0.18
52W Low $10.48High $35.65

Volume 2.10M

Average 3.06M

TXG EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

10x Genomics, Inc.NASDAQ: TXG

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$16.06M, compared with -$15.95M a year earlier. Trailing-twelve-month EBITDA was $37.56M.

Context

  • EBITDA amounted to 0.6% of revenue in FY2025, down 21.3 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 11 analysts of -$30.39M (-877.3%) for the fiscal year ending Dec 2026, a slowdown from the +102.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$16.06M-78.8% QoQ
Last fiscal yearDec 2025
$3.91M+102.9% YoY
LTMSep 2026
$37.56M+221.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.7%-129.4%-128.7 pp
1 year+102.9%-877.3%-980.2 pp
3-year CAGR—+33.3%—
5-year CAGR+99.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
3.91M USD
Year-over-year change
+102.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TXG compares with its peers on the latest reported figures

  • TXG's LTM Sep 2026 EBITDA of $37.56M is the 7th highest of the 9 companies compared; the peer median is $609.04M.
  • Its year-over-year change of +221.9% is the highest of 9, against a peer median of -4.2%.
  • EBITDA amounts to 6.1% of revenue for TXG, versus a peer median of 27.9%.
TXG Competitors Peer median
EBITDA for TXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$2.04B +13.2%-1.2%27.6%
ILMNIllumina, Inc.LTM Jun 2026$1.36B -23.6%—30.3%
RVTYRevvity, Inc.LTM Jul 2026$767M -6.7%-13.5%26.3%
QGENQiagen N.V.LTM Jun 2026$703.39M -1.6%-2.7%33.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$514.7M -22.7%—19.9%
TECHBio-Techne CorporationLTM Sep 2026$328.77M +48.3%-9.1%26.8%
TXG10x Genomics, Inc.LTM Sep 2026$37.56M +221.9%—6.1%
LABStandard BioTools Inc.LTM Mar 2026-$81.51M +5.7%—94.5%
TWSTTwist Bioscience CorporationLTM Sep 2026-$129.8M -149.9%—28.3%
Peer median (excluding TXG) $609.04M-4.2%-5.9%27.9%

Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue490.49M516.41M618.73M610.79M642.82M
Cost of Revenue74.09M120.39M209.41M196.3M198.94M
Gross Profit416.4M396.02M409.31M414.48M443.88M
Gross Margin84.9%76.7%66.2%67.9%69.1%
Research & Development211.75M265.67M270.33M264.7M238.63M
Selling, General & Admin257.56M298.3M343.33M344.34M316.13M
Operating Expenses469.31M563.97M674.64M609.04M554.77M
Depreciation & Amortization28.25M33.01M43.62M43.71M43.82M
EBITDA(24.6M)(128.49M)(205.11M)(133.99M)3.91M
EBITDA Margin-5.0%-24.9%-33.2%-21.9%0.6%
Operating Income(52.91M)(167.94M)(265.33M)(194.56M)(110.89M)
Operating Margin-10.8%-32.5%-42.9%-31.9%-17.2%
Interest Income206K6.65M16.91M18.45M20.05M
Interest Expense866K476K33K4K0
Other Income / Expenses(802K)5.97M16.57M16.86M70.98M
Income Before Tax(53.72M)(161.97M)(248.76M)(177.7M)(39.91M)
Pre-Tax Margin-11.0%-31.4%-40.2%-29.1%-6.2%
Income Tax Expense4.51M4.03M6.34M4.93M3.64M
Net Income(58.22M)(166M)(255.1M)(182.63M)(43.54M)
Net Margin-11.9%-32.1%-41.2%-29.9%-6.8%
EPS (Basic)(0.53)(1.46)(2.18)(1.52)(0.35)
EPS (Diluted)(0.53)(1.46)(2.18)(1.52)(0.35)
Weighted Avg Shares110.35M113.86M117.17M120.45M124.75M
Weighted Avg Shares (Diluted)110.35M113.86M117.17M120.45M124.75M

10x Genomics, Inc.

NASDAQ:TXG

Intrinsic Alpha fair value

Locked

Current Price

$57.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.